MX341474B - Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la fosfodiesterasa tipo 4 ( pde4). - Google Patents
Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la fosfodiesterasa tipo 4 ( pde4).Info
- Publication number
- MX341474B MX341474B MX2011010146A MX2011010146A MX341474B MX 341474 B MX341474 B MX 341474B MX 2011010146 A MX2011010146 A MX 2011010146A MX 2011010146 A MX2011010146 A MX 2011010146A MX 341474 B MX341474 B MX 341474B
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- alkoxy
- hydrogen
- substituted
- completely
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/04—Drugs for disorders of the urinary system for urolithiasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
Abstract
Se describen compuestos de fórmula I. (ver fórmula (I)) que son nuevos inhibidores de PDE4 efectivos, en donde R1 es hidroxilo, alcoxi C1-4, cicloalcoxi C3-7, cicloalquilmetoxi C3-7, 2,2-difluoroetoxi, o alcoxi C1-4 completa o predominantemente sustituido con flúor, R2 es hidroxilo, alcoxi C1-4, cicloalcoxi C3-7, cicloalquilmetoxi C3-7, 2,2-difluoroetoxi, o alcoxi C1-4 completa o predominantemente sustituido con flúor, o en donde R1 y R2 juntos son un grupo alquilendioxi C1-2, R3 es hidrógeno o alquilo C1-4, R31 es hidrógeno o alquilo 01-4, o, en una primera modalidad (modalidad a) de acuerdo a la presente invención, R4 es -O-R41, en donde R41 es hidrógeno, alquilo C1-4, alcoxi C1-4-alquilo C1-4, hidroxialquilo C2-4, alquilcarbonilo C1-7, o alquilo C1-4 completa o predominantemente sustituido con flúor, y R5 es hidrógeno o alquilo C1-4, o, en una segunda modalidad (modalidad b) de acuerdo a la presente invención, R4 es hidrógeno o alquilo C1-4, y R5 es -O-R51, en donde R51 es hidrógeno, alquilo C1-4, alcoxi C1-4-alquilo C1-4, hidroxi alquilo C2-4, alquilcarbonilo C1-7, o alquilo C1-4 completa o predominantemente sustituido con flúor, Har es opcionalmente sustituido por R6 y/o R7 y/o R8, y es un radical heteroarilo insaturado o parcialmente saturado monocíclico o bicíclico fusionado de 5 a 10 miembros que comprende 1 a 4 heteroátomos seleccionados independientemente del grupo que consiste de oxígeno, nitrógeno y azufre.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04004973 | 2004-03-03 | ||
EP04106359 | 2004-12-07 | ||
PCT/EP2005/050931 WO2005085225A1 (en) | 2004-03-03 | 2005-03-02 | Novel hydroxy-6-heteroarylphenanthridines and their use as pde4 inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
MX341474B true MX341474B (es) | 2016-08-19 |
Family
ID=34921303
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011010146A MX341474B (es) | 2004-03-03 | 2005-03-02 | Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la fosfodiesterasa tipo 4 ( pde4). |
MXPA06009695A MXPA06009695A (es) | 2004-03-03 | 2005-03-02 | Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4). |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA06009695A MXPA06009695A (es) | 2004-03-03 | 2005-03-02 | Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la fosfodiesterasa tipo 4 (pde4). |
Country Status (29)
Country | Link |
---|---|
US (8) | US8003798B2 (es) |
EP (2) | EP1723135B1 (es) |
JP (2) | JP4801039B2 (es) |
KR (2) | KR101152488B1 (es) |
CN (6) | CN104761545A (es) |
AR (1) | AR049319A1 (es) |
AU (1) | AU2005219576B2 (es) |
BR (1) | BRPI0508321B1 (es) |
CA (1) | CA2557752C (es) |
CO (1) | CO5700749A2 (es) |
CY (2) | CY1114319T1 (es) |
DK (2) | DK1723135T5 (es) |
EA (2) | EA014155B1 (es) |
ES (2) | ES2427256T3 (es) |
HK (4) | HK1207635A1 (es) |
HR (2) | HRP20130828T1 (es) |
IL (2) | IL177073A (es) |
ME (1) | ME01955B (es) |
MX (2) | MX341474B (es) |
NO (2) | NO336538B1 (es) |
NZ (1) | NZ549108A (es) |
PL (2) | PL2589599T4 (es) |
PT (2) | PT2589599E (es) |
RS (2) | RS53543B1 (es) |
SG (1) | SG182194A1 (es) |
SI (2) | SI2589599T1 (es) |
TW (2) | TWI404704B (es) |
WO (1) | WO2005085225A1 (es) |
ZA (1) | ZA200606176B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60311662T2 (de) | 2002-08-29 | 2007-10-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
JP4728259B2 (ja) | 2004-02-18 | 2011-07-20 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 効果的なホスホジエステラーゼ(pde)4インヒビターとしての新規のグアニジニル置換されたヒドロキシ−6−フェニルフェナントリジン |
KR101152488B1 (ko) | 2004-03-03 | 2012-07-02 | 니코메드 게엠베하 | 신규 히드록시-6-헤테로아릴페난트리딘 및 pde4 억제제로서의 이의 용도 |
ES2342728T3 (es) | 2005-02-01 | 2010-07-13 | Nycomed Gmbh | Nuevas 6-piridilfenantridinas. |
EA200701815A1 (ru) * | 2005-03-02 | 2008-02-28 | Никомед Гмбх | 6-гетероарил-1,2,3,4,4а,10в-гексагидрофенантридины в качестве pde-4 ингибиторов для лечения воспалительных заболеваний |
SI1856093T1 (sl) | 2005-03-02 | 2010-03-31 | Nycomed Gmbh | Hidrokloridna sol R aR bR dimetoksipiridin il etoksi metoksi a b heksahidrofenantridin ola |
US20100179131A1 (en) | 2006-09-07 | 2010-07-15 | Nycomed Gmbh | Combination treatment for diabetes mellitus |
US8013003B2 (en) * | 2007-05-17 | 2011-09-06 | Cortex Pharmaceuticals, Inc. | Di-substituted amides for enhancing glutamatergic synaptic responses |
WO2009025823A1 (en) * | 2007-08-21 | 2009-02-26 | Amgen Inc. | Phosphodiesterase 10 inhibitors |
WO2009109525A1 (en) * | 2008-03-03 | 2009-09-11 | Nycomed Gmbh | Use of a specific pde4 inhibitor for the treatment and/or prophylaxis of non-alcoholic fatty liver disease |
AR074318A1 (es) | 2008-11-14 | 2011-01-05 | Nycomed Gmbh | Derivados heterociclicos de pirazolona, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de enfermedades de las vias respiratorias. |
JP2017503814A (ja) * | 2014-01-22 | 2017-02-02 | タケダ ゲー・エム・ベー・ハーTakeda GmbH | 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のpde4インヒビターを用いた(およびロイコトリエン調節薬と組み合わせて用いた)治療 |
CN103936661B (zh) * | 2014-04-04 | 2016-08-24 | 常州大学 | 一种6-烷基菲啶衍生物的合成方法 |
JP2018521077A (ja) * | 2015-07-29 | 2018-08-02 | タケダ ゲー・エム・ベー・ハーTakeda GmbH | 糖尿病性腎症を治療するためのpde4阻害剤 |
CN110099686B (zh) * | 2016-08-26 | 2022-04-15 | 武田药品工业株式会社 | 非酒精性脂肪性肝病的治疗 |
CN110573148A (zh) * | 2017-03-16 | 2019-12-13 | 武田有限公司 | 特发性肺纤维化的治疗 |
WO2020113088A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Diarylhydantoin compounds and methods of use thereof |
EP3886854A4 (en) * | 2018-11-30 | 2022-07-06 | Nuvation Bio Inc. | PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE |
TWI785816B (zh) * | 2019-08-30 | 2022-12-01 | 國立陽明交通大學 | 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法 |
TWI753296B (zh) * | 2019-08-30 | 2022-01-21 | 國立陽明交通大學 | 11-芳香基噌啉[2,3-f]菲啶鹽化合物及其製造方法 |
Family Cites Families (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9027055D0 (en) | 1990-12-13 | 1991-02-06 | Sandoz Ltd | Organic compounds |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
PT706513E (pt) | 1993-07-02 | 2002-10-31 | Byk Gulden Lomberg Chem Fab | Benzimidazois substituidos por fluoralcoxi e sua utilizacao como inibidores de fosfodiesterase nucleotidica ciclica |
US6191138B1 (en) | 1996-01-31 | 2001-02-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridines |
US6127378A (en) | 1996-03-26 | 2000-10-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridines substituted in the 6 position |
PT889886E (pt) | 1996-03-26 | 2003-02-28 | Altana Pharma Ag | Novas fenantridinas substituidas na posicao 6 |
JPH1020274A (ja) * | 1996-07-05 | 1998-01-23 | Fujitsu Ltd | 液晶表示駆動回路及び液晶表示装置 |
SK283269B6 (sk) | 1996-11-11 | 2003-04-01 | Altana Pharma Ag | Benzonaftyridíny, farmaceutický prostriedok s ich obsahom a ich použitie |
ATE248167T1 (de) | 1997-03-07 | 2003-09-15 | Altana Pharma Ag | Tetrazole derivate |
AU8106598A (en) | 1997-06-03 | 1998-12-21 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine |
US6214839B1 (en) | 1997-07-25 | 2001-04-10 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Substituted 6-alkylphenanthridines |
ES2189235T3 (es) | 1997-07-25 | 2003-07-01 | Altana Pharma Ag | 6-fenilfenantridinas sustituidas. |
US6410551B1 (en) | 1997-07-25 | 2002-06-25 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Tetrazole derivatives |
CA2309175A1 (en) * | 1997-11-04 | 1999-05-14 | Pfizer Products Inc. | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors |
ATE234301T1 (de) * | 1998-05-05 | 2003-03-15 | Altana Pharma Ag | Neue benzonaphtyridin-n-oxide |
US6436952B1 (en) | 1998-08-31 | 2002-08-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Benzonaphthyridine-N-oxides comprising a PDE3 and PDE4 inhibiting activity |
ATE312081T1 (de) | 1999-01-15 | 2005-12-15 | Altana Pharma Ag | 6-phenylphenanthridine mit pde-iv hemmender wirkung |
JP2002534506A (ja) * | 1999-01-15 | 2002-10-15 | ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング | Pde−iv抑制作用を有する多重に置換された6−フェニルフェナントリジン |
AU2107700A (en) * | 1999-01-15 | 2000-08-01 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phenanthridine-n-oxides with pde-iv inhibiting activity |
SI1147103T1 (en) * | 1999-01-15 | 2005-10-31 | Altana Pharma Ag | Phenantrhridine-n-oxides with pde-iv inhibiting activity |
WO2000042019A1 (en) * | 1999-01-15 | 2000-07-20 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 6-arylphenanthridines with pde-iv inhibiting activity |
IL148807A0 (en) * | 1999-10-25 | 2002-09-12 | Byk Gulden Lomberg Chem Fab | Tetrahydrothiopyran derivatives and pharmaceutical compositions containing the same |
AU782908B2 (en) | 2000-01-11 | 2005-09-08 | Altana Pharma Ag | Phenanthridine-N-oxides |
EP1270577B1 (en) | 2000-03-23 | 2006-12-06 | Takeda Pharmaceutical Company Limited | Furoisoquinoline derivatives, process for producing the same and use thereof |
AU2001281965A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Novel 6-phenylphenanthridines |
AU2001267589A1 (en) | 2000-07-14 | 2002-01-30 | Byk Gulden Lomberg Chemische Fabrik G.M.B.H. | Cycloalkyl - or cycloalkylmethyl-substituted 6-phenylphenanthridines |
ES2236288T3 (es) * | 2000-07-14 | 2005-07-16 | Altana Pharma Ag | 6-heteroarilfenantridinas. |
CA2438717C (en) | 2001-02-21 | 2011-08-30 | Altana Pharma Ag | 6-phenylbenzonaphthyridines |
JP2005537312A (ja) | 2002-08-17 | 2005-12-08 | アルタナ ファルマ アクチエンゲゼルシャフト | 新規のフェナントリジン |
EP1581533A2 (en) | 2002-08-17 | 2005-10-05 | ALTANA Pharma AG | Novel benzonaphthyridines |
ATE348616T1 (de) * | 2002-08-29 | 2007-01-15 | Altana Pharma Ag | 2-hydroxy-6-phenylphenanthridine als pde-4-hemmer |
DE60311662T2 (de) * | 2002-08-29 | 2007-10-25 | Altana Pharma Ag | 3-hydroxy-6-phenylphenanthridine als pde-4 inhibitoren |
RU2247262C2 (ru) | 2003-05-19 | 2005-02-27 | Федеральное государственное унитарное предприятие Российский Федеральный Ядерный Центр-Всероссийский Научно-исследовательский институт технической физики им. акад. Е.И. Забабахина (РФЯЦ- ВНИИТФ) | Плунжерный насос сверхвысокого давления |
JP4728259B2 (ja) | 2004-02-18 | 2011-07-20 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 効果的なホスホジエステラーゼ(pde)4インヒビターとしての新規のグアニジニル置換されたヒドロキシ−6−フェニルフェナントリジン |
AR049419A1 (es) | 2004-03-03 | 2006-08-02 | Altana Pharma Ag | Hidroxi-6-fenilfenantridinas sustituidas con heterociclilo |
KR101152488B1 (ko) | 2004-03-03 | 2012-07-02 | 니코메드 게엠베하 | 신규 히드록시-6-헤테로아릴페난트리딘 및 pde4 억제제로서의 이의 용도 |
AU2005220034A1 (en) * | 2004-03-09 | 2005-09-15 | Nycomed Gmbh | Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors |
WO2005087745A1 (en) * | 2004-03-10 | 2005-09-22 | Altana Pharma Ag | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors |
BRPI0508473A (pt) | 2004-03-10 | 2007-07-31 | Altana Pharma Ag | hidróxi-6-fenilfenantridinas contendo tiol e seu uso como inibidores de pde4 |
AU2005219581A1 (en) * | 2004-03-10 | 2005-09-15 | Nycomed Gmbh | Novel difluoroethoxy-substituted hydroxy-6-phenylphenanthridines and their use as PDE4 inhibitors |
SI1856093T1 (sl) | 2005-03-02 | 2010-03-31 | Nycomed Gmbh | Hidrokloridna sol R aR bR dimetoksipiridin il etoksi metoksi a b heksahidrofenantridin ola |
-
2005
- 2005-03-02 KR KR1020117030419A patent/KR101152488B1/ko not_active IP Right Cessation
- 2005-03-02 ME MEP-2014-113A patent/ME01955B/me unknown
- 2005-03-02 CN CN201510101394.4A patent/CN104761545A/zh active Pending
- 2005-03-02 DK DK05716889.0T patent/DK1723135T5/da active
- 2005-03-02 CN CN201510101203.4A patent/CN104803974A/zh active Pending
- 2005-03-02 KR KR1020067019892A patent/KR101152439B1/ko not_active IP Right Cessation
- 2005-03-02 WO PCT/EP2005/050931 patent/WO2005085225A1/en active Application Filing
- 2005-03-02 AR ARP050100780 patent/AR049319A1/es not_active Application Discontinuation
- 2005-03-02 EP EP05716889.0A patent/EP1723135B1/en active Active
- 2005-03-02 AU AU2005219576A patent/AU2005219576B2/en not_active Ceased
- 2005-03-02 PL PL12196702T patent/PL2589599T4/pl unknown
- 2005-03-02 MX MX2011010146A patent/MX341474B/es unknown
- 2005-03-02 ES ES05716889T patent/ES2427256T3/es active Active
- 2005-03-02 PT PT12196702T patent/PT2589599E/pt unknown
- 2005-03-02 SG SG2012043295A patent/SG182194A1/en unknown
- 2005-03-02 JP JP2007501289A patent/JP4801039B2/ja not_active Expired - Fee Related
- 2005-03-02 NZ NZ549108A patent/NZ549108A/en unknown
- 2005-03-02 CN CN201510100429.2A patent/CN104817534A/zh active Pending
- 2005-03-02 SI SI200531890T patent/SI2589599T1/sl unknown
- 2005-03-02 MX MXPA06009695A patent/MXPA06009695A/es active IP Right Grant
- 2005-03-02 SI SI200531772T patent/SI1723135T1/sl unknown
- 2005-03-02 PT PT57168890T patent/PT1723135E/pt unknown
- 2005-03-02 CN CN2011101613875A patent/CN102295634A/zh active Pending
- 2005-03-02 EA EA200601568A patent/EA014155B1/ru not_active IP Right Cessation
- 2005-03-02 CN CNA2005800057687A patent/CN1922170A/zh active Pending
- 2005-03-02 ES ES12196702.0T patent/ES2505473T3/es active Active
- 2005-03-02 RS RSP20140498 patent/RS53543B1/en unknown
- 2005-03-02 US US10/590,803 patent/US8003798B2/en active Active
- 2005-03-02 PL PL05716889T patent/PL1723135T3/pl unknown
- 2005-03-02 EA EA201000494A patent/EA017282B1/ru not_active IP Right Cessation
- 2005-03-02 CN CN201510100383.4A patent/CN104803973A/zh active Pending
- 2005-03-02 RS RS20130349A patent/RS52916B/en unknown
- 2005-03-02 EP EP20120196702 patent/EP2589599B1/en active Active
- 2005-03-02 CA CA2557752A patent/CA2557752C/en not_active Expired - Fee Related
- 2005-03-02 BR BRPI0508321-4A patent/BRPI0508321B1/pt not_active IP Right Cessation
- 2005-03-02 DK DK12196702T patent/DK2589599T3/da active
- 2005-03-03 TW TW100110218A patent/TWI404704B/zh not_active IP Right Cessation
- 2005-03-03 TW TW094106493A patent/TWI372750B/zh not_active IP Right Cessation
-
2006
- 2006-07-25 IL IL177073A patent/IL177073A/en not_active IP Right Cessation
- 2006-07-26 ZA ZA200606176A patent/ZA200606176B/xx unknown
- 2006-07-28 CO CO06074146A patent/CO5700749A2/es active IP Right Grant
- 2006-09-19 NO NO20064221A patent/NO336538B1/no not_active IP Right Cessation
-
2011
- 2011-01-21 JP JP2011011310A patent/JP5193320B2/ja active Active
- 2011-05-19 US US13/111,544 patent/US8324391B2/en active Active
- 2011-05-19 US US13/111,524 patent/US8318944B2/en not_active Expired - Fee Related
-
2012
- 2012-08-06 IL IL221323A patent/IL221323A0/en not_active IP Right Cessation
- 2012-10-26 US US13/661,897 patent/US8455653B2/en not_active Expired - Fee Related
-
2013
- 2013-04-30 US US13/873,670 patent/US8883818B2/en not_active Expired - Fee Related
- 2013-09-05 HR HRP20130828TT patent/HRP20130828T1/hr unknown
- 2013-09-09 CY CY20131100770T patent/CY1114319T1/el unknown
-
2014
- 2014-09-08 CY CY20141100722T patent/CY1115536T1/el unknown
- 2014-09-17 HR HRP20140892TT patent/HRP20140892T1/hr unknown
- 2014-10-07 US US14/508,077 patent/US9149479B2/en not_active Expired - Fee Related
- 2014-12-18 NO NO20141541A patent/NO338326B1/no not_active IP Right Cessation
-
2015
- 2015-08-25 US US14/834,709 patent/US9387205B2/en not_active Expired - Fee Related
- 2015-08-26 HK HK15108262.7A patent/HK1207635A1/xx unknown
- 2015-09-16 HK HK15109032.4A patent/HK1208447A1/xx unknown
- 2015-09-30 HK HK15109596.2A patent/HK1208865A1/xx unknown
-
2016
- 2016-01-18 HK HK16100490.7A patent/HK1214812A1/zh unknown
- 2016-06-10 US US15/179,268 patent/US9962377B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX341474B (es) | Nuevas hidroxi-6-heteroarilfenantridinas y su uso como inhibidores de la fosfodiesterasa tipo 4 ( pde4). | |
WO2005087745A8 (en) | Novel amido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | |
WO2005087744A8 (en) | Novel thio-containing hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | |
WO2005084104A3 (en) | Novel isoamido-substituted hydroxy-6-phenylphenanthridines and their use as pde4 inhibitors | |
HK1078850A1 (en) | Novel alkoxypyridine-derivatives | |
PE20130376A1 (es) | [1,8]naftiridinas sustituidas por 2,4-diarilo como inhibidores de quinasas para uso contra el cancer | |
MX2009006864A (es) | Inhibidores novedosos de c jun-n-terminal cinasas. | |
ATE357445T1 (de) | Darstellung von 1h-imidazo(4,5-c)chinolin-4- aminen über neue 1h-imidazo(4,5-c)chinolin-4- cyano- und 1h-imidazo(4,5-c)chinolin-4-carboxamid intermediate | |
PT706513E (pt) | Benzimidazois substituidos por fluoralcoxi e sua utilizacao como inibidores de fosfodiesterase nucleotidica ciclica | |
CO5611147A2 (es) | Derivados de nicotinamida utiles como inhibidores p38 | |
NO20063132L (no) | Naftyridinderivater og deres anvendelse som modulatorer av muskarinreceptorer | |
RS52937B (en) | SULFONYLPYROLS AS HDAC INHIBITORS | |
MXPA02011426A (es) | Derivados de b-carbolina utiles como inhibidores de fosfodiesterasa. | |
NO20060664L (no) | N-substituerte benzimidazolyl C-kit inhibitorer | |
AP1789A (en) | Tropane derivatives useful in therapy. | |
ECSP045392A (es) | Moduladores tetrahidropiranil-ciclopentil-tetrahidropiridopiridinicos de la actividad de receptores de quimiocina | |
NO20064220L (no) | Nye heterocyklylsubstituerte hydroksy-6-fenylfenantridiner og deres anvendelse som PDE4-inhibitorer | |
ATE304533T1 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
MXPA04002423A (es) | Derivados de piperazina con actividad antagonista del receptor ccr1. | |
TW200519112A (en) | Tropane derivatives | |
PE20071087A1 (es) | Derivados espirociclicos como inhibidores de pde7 | |
ATE348101T1 (de) | Carbolin derivate als hemmstoffe von phospphodiesterase 5 (pde5) zur behandlung kardiovaskulärer erkrankungen und der erektilen dysfunktion | |
ATE368040T1 (de) | Substituierte tetrazyklische pyprolochinolonderivate als phosphodiesterase- inhibitoren | |
MX2007006776A (es) | Compuestos de espirotropano novedosos y metodos para la modulacion de la actividad del receptor de quimioquina. | |
TW200503722A (en) | Substituted 7-aza-quinazoline compounds |